Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)

Trial Purpose and Description

The objective of this study is to determine the safety and efficacy of transcatheter aortic valve replacement (TAVR) via a transfemoral approach in HF patients with moderate AS as compared with OHFT.

Ages: 18 years and older

Gender: Both


Eligibility Criteria

Inclusion Criteria:

Candidates are excluded from the study if any of the following conditions are present:

  1. Age ≥18 years
  2. NYHA class ≥ 2
  3. NT-proBNP > 1500 pg/mL (or BNP > 400 pg/mL) or hospitalization for HF within the last year
  4. Under appropriate guideline-directed HF therapy (including cardiac resynchronization therapy) for a minimum of 3 months.

    -Patients are expected to be on appropriate pharmacologic therapy and if indicated CRT for heart failure. (12, 13) Patients with aortic stenosis may not be able to tolerate maximal doses of heart failure medications and no specific guidelines exist for the medical treatment of heart failure in the setting of aortic stenosis. It is expected that the heart failure PI will review the medical therapy and confirm that it is appropriate for the patient's condition.

  5. Moderate AS confirmed by the echo core lab. Moderate AS is defined as an aortic valve area (AVA) >1.0 cm2 and ≤1.5 cm2 on rest echo or if ≤1.0 cm2 at rest and low flow AS is suspected an AVA > 1.0 cm2 with low dose dobutamine stress echo (DSE). Patients with AVA<1.0 cm2 but with an indexed AVA of >0.6cm2 on either rest or DSE are also eligible.

    Note: Typically such cases will demonstrate,

    • Mean trans-aortic gradient (MG) ≥ 20 mmHg and < 40 mmHg at rest and aortic valve area (AVA) > 1.0 cm2 and ≤1.5 cm2 (or AVA < 1.0 cm2 but indexed AVA > 0.6 cm2) at rest OR
    • Mean trans-aortic gradient (MG) ≥ 20 mmHg and < 40 mmHg and aortic valve area (AVA) ≤1.0 cm2 at rest AND MG < 40 mmHg and aortic valve area (AVA) >1.0 cm2 (or AVA < 1.0 cm2 but indexed AVA > 0.6 cm2) with low dose dobutamine stress echo (DSE).

    In atypical cases (for example mean gradient is below 20 mmHg but valve area is consistent with moderate AS, the final eligibility determination in regards to diagnosis of moderate AS will be made by the echocardiographic core lab.

  6. Left ventricular (LV) ejection fraction (EF) < 50% at rest
  7. Anatomically suitable for transfemoral TAVR with the SAPIEN 3 THV
  8. Able to provide independent informed consent (i.e., not requiring a legally authorized representative)

Exclusion Criteria

Candidates are excluded from the study if any of the following conditions are present:

  1. LVEF < 20% or persistent need for intravenous inotropic support
  2. Hospitalization for acute decompensated HF within 2 weeks prior to randomization
  3. Cardiac resynchronization therapy (CRT) device implantation within 3 months prior to randomization
  4. Coronary artery revascularization (PCI or CABG) within 3 months prior to randomization
  5. In need and suitable for revascularization per heart team consensus
  6. Severe aortic and/or mitral regurgitation
  7. Congenital unicuspid or congenital bicuspid aortic valve
  8. Concomitant non-aortic valvular disease with a formal indication for valve surgery per established guidelines (ESC/ACC/AHA)
  9. Previous aortic valve replacement (mechanical or bioprosthetic)
  10. Severe RV dysfunction
  11. Previous stroke with permanent disability (modified Rankin score ≥ 2)
  12. Chronic obstructive pulmonary disease (COPD) GOLD 4 (FEV1 <30% predicted, <50% predicted with chronic respiratory failure present (long-term oxygen therapy), or FEV1/FVC <0.70)
  13. Severe chronic kidney disease: glomerular filtration rate (GFR) < 30 mL/min by MDRD or need for renal replacement therapy
  14. Gastrointestinal (GI) bleeding within the past 3 months
  15. Liver cirrhosis Child-Pugh C
  16. Active systemic infection, including active endocarditis
  17. Unwilling to accept blood transfusion
  18. Evidence of intracardiac mass, thrombus or vegetation
  19. Absence of minimum amount of aortic valve calcification necessary for TAVR with the SAPIEN 3 THV
  20. Hypersensitivity or contraindication to clopidogrel, aspirin, or to oral anticoagulation if indicated (e.g. subject in atrial fibrillation)
  21. Sensitivity to contrast media which cannot be adequately pre-medicated
  22. Women of child-bearing potential
  23. Clinical signs of dementia
  24. Other medical, social, or psychological conditions that precludes appropriate consent and follow-up
  25. Life expectancy < 2 years due to cancer or other non-cardiac chronic diseases
  26. Unwillingness to undergo follow-up investigations
  27. Currently participating in an investigational drug or another device trial that has not reached its primary endpoint (excluding registries)

Cardiovascular Research Foundation

Dates: 10/26/2017 - 03/30/2018

Last Updated: 10/27/2017

Study HIC#: 2000021341

Get Involved

For more information about this study, contact:
Linda T Levesque
+1 203-737-6483
linda.levesque@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

John Kiene Forrest

Principal Investigator

Sub-Investigators